ESC and ERA target the heart-kidney spiral with first joint guidelines
Cardiovascular disease and chronic kidney disease have long been treated as separate problems in many clinics. These new European recommendations treat them as a single clinical loop, one in which damage to the heart and damage to the kidneys can accelerate each other and pull patients toward heart failure, dialysis, stroke, and premature death.
The European Society of Cardiology, working with the European Renal Association, has issued its first guidelines focused specifically on managing cardiovascular disease alongside CKD. The document was published in the European Heart Journal and presented at ESC Congress 2026. Its central message is blunt: if clinicians wait until kidney disease is obvious, a large share of avoidable cardiovascular and renal injury has already occurred.
Screening moves to the front of cardiovascular care
The guidelines recommend screening every patient with cardiovascular disease for CKD at the time cardiovascular disease is diagnosed. The workup relies on two routine tests: estimated glomerular filtration rate, derived from blood creatinine, and urine albumin-to-creatinine ratio. In practical terms, this means kidney assessment should no longer be an afterthought reserved for nephrology visits or late-stage referral.
This approach reflects the biology of the syndrome. Reduced filtration, albumin leakage, and systemic vascular injury rarely appear in isolation. Once kidney impairment begins, it can worsen blood pressure control, heighten inflammatory and thrombotic stress, and make the cardiovascular system more vulnerable to ischemia and congestion. In the opposite direction, heart disease can reduce renal perfusion and expose the kidneys to ongoing hemodynamic strain. The cycle is self-reinforcing unless clinicians identify it early.
A single blood test and a urine test can expose risk long before symptoms force the issue.
Risk triage is no longer optional
After screening, the guidelines move to triage, focusing on the likelihood of kidney failure and the patient’s broader cardiovascular risk. Validated scoring tools that account for kidney function are recommended. This is a meaningful shift because a patient with stable symptoms may still be sitting on a steep renal risk curve, while another may face high cardiovascular danger despite modest changes in creatinine or albuminuria.
The guideline authors built the recommendations around the acronym STAMP on CKD: Screen, Triage, Address CKD Risk, Modify CVD management, and Plan health services. The structure is simple, but the clinical intent is not. It forces care teams to ask the right questions in the right order, starting with whether kidney disease is present and ending with how the healthcare system will keep the patient from falling through the cracks.
Earlier use of proven therapies may blunt both risks
Once CKD is identified, the document emphasizes early treatment with proven, cost-effective therapies. RAS inhibitors and SGLT2 inhibitors are named as especially important, alongside statin-based therapy. These treatments matter because they act on the core physiology of cardiorenal injury. RAS inhibition lowers intraglomerular pressure and helps reduce proteinuric stress, while SGLT2 inhibition has become a major tool for slowing renal decline and lowering cardiovascular complications. Statin therapy adds vascular risk reduction in a population already burdened by diffuse atherosclerotic threat.
The recommendations also address a common therapeutic trap: cardiovascular drugs that are routine in patients with normal renal function may need adjustment when kidney clearance is reduced. Some medicines accumulate, others become less predictable, and dosing choices can change the balance between benefit and harm. The guideline therefore provides advice on which cardiovascular treatments can be used safely when CKD alters drug handling.
One clinical consequence follows directly from that pharmacology: the same patient may need both more aggressive protection and more careful prescribing at the same time.
Coordination between specialties becomes part of the treatment plan
The final part of the strategy is organizational rather than pharmacologic, but it is just as important. Patients at highest risk need to be identified quickly and moved into care pathways that connect cardiology and nephrology without delay. The guideline authors stress active communication between specialties, because CKD often complicates treatment decisions that appear straightforward in a single-disease model.
This multidisciplinary model is not a courtesy; it is a response to the mechanics of the disease itself. Heart and kidney failure can progress on different timelines, but they converge on the same patient, often in the same year, sometimes in the same hospitalization. If cardiologists do not ask about albuminuria and nephrologists do not review cardiovascular risk with equal seriousness, treatment plans remain incomplete. Shared care also creates room for family caregivers and patients to participate in decisions about surveillance, drug therapy, and referral timing.
The patient version of the guidelines is meant to support that process. Clearer explanations can help people understand why repeated blood and urine tests matter, why a new medication may be introduced even before symptoms worsen, and why coordination across clinics can change long-term outcomes.
A large burden across Europe, and a narrow window to act earlier
CKD affects an estimated 100 million people across Europe, and the condition markedly raises the risk of cardiovascular disease. The burden is not just epidemiologic; it is operational. Patients often move between services without a unified plan, and the result is delayed recognition of renal decline, missed opportunities for albuminuria treatment, and avoidable cardiovascular complications.
The new guidelines are explicit about the stakes. CKD can accelerate cardiovascular disease, and cardiovascular disease can accelerate CKD, driving events and dialysis much earlier in life. The document points clinicians toward a more active model: screen early, triage intelligently, begin evidence-based therapy sooner, adjust cardiovascular drugs when renal function demands it, and build care pathways that make collaboration routine rather than exceptional.
For now, the biggest unanswered issue is not whether the heart-kidney relationship exists. It is whether health systems will adopt the screening and treatment sequence quickly enough to change outcomes for the millions already living inside that cycle.